CRSP
Reserved
Reserved
CRISPR Therapeutics sale del 2,2%: rimbalzo sulla media a 20 sedute, ma il tetto è vicino
EXECUTIVE VIEW
CRISPR Therapeutics sale del 2,2% rimbalzando sulla media a 20 sedute e si ferma sotto la media a 200 settimane. Analisi tecnica delle azioni CRISPR Therapeutics: segnale di acquisto in guadagno del 3,5%, price action in ripresa e flusso di denaro ancora negativo.
Reserved analysis
Subscribe to read →
CRISPR Therapeutics gains 2.2% on a bounce off its 20-day average, ceiling just overhead
EXECUTIVE VIEW
CRISPR Therapeutics stock gains 2.2% on a bounce off its 20-day average and stalls under the 200-week average. Weekly technical analysis of a swing trading setup among US stocks: the buy signal is 3.5% in profit, with money flow still negative.
Reserved analysis
Subscribe to read →